Weight-loss and diabetes drugs reduced the risk of developing Alzheimer’s, an independent study published Monday showed.

T he newest weight-loss drugs, Wegovy and Zepbound, are incredibly popular. But doctors are still learning about all of the ...

A study shows GLP-1 weight-loss drugs reduce Alzheimer’s risk but increase arthritis, kidney, and pancreas issues.

About 140,400 obese patients in Massachusetts were prescribed medications like Wegovy and Zepbound in 2024, a 255 percent ...

Two recent disappointing clinical trials of highly-anticipated weight-loss drugs have made it clear that it is too early to ...

A new study highlighted Monday the potential benefits of popular diabetes drugs on a wide range of health issues including ...

The market for GLP-1 drugs is projected to exceed $200 billion in annual sales by 2031, according to Morningstar Equity Research. Current market leaders include Novo Nordisk NVO and Eli Lilly LLY with ...

A new study highlighted Monday the potential benefits of popular diabetes drugs on a wide range of health issues including dementia and cardiovascular diseases, although experts warned against seeing ...

The findings, based on an analysis of records from 2.5 million VA patients, support much of what scientists already suspected ...

Demand for weight-loss medications sold under brand names such as Ozempic and Wegovy continues to surge, with a recent study ...

Viking Therapeutics investors face challenges as stock plummets, cash runway helps but betting on early stage biopharma ...

A study published in Nature Medicine looks at the health risks and benefits linked to GLP-1 receptor agonists. Prof Naveed Sattar, Professor of Cardiometabolic Medicine/Honorary Consultant, University ...